[go: up one dir, main page]

NO20040598L - 5-CNAC som oralt avleveringsmiddel for paratyreoidhormonfragmenter. - Google Patents

5-CNAC som oralt avleveringsmiddel for paratyreoidhormonfragmenter.

Info

Publication number
NO20040598L
NO20040598L NO20040598A NO20040598A NO20040598L NO 20040598 L NO20040598 L NO 20040598L NO 20040598 A NO20040598 A NO 20040598A NO 20040598 A NO20040598 A NO 20040598A NO 20040598 L NO20040598 L NO 20040598L
Authority
NO
Norway
Prior art keywords
parathyroid hormone
oral delivery
cnac
delivery agent
hormone fragments
Prior art date
Application number
NO20040598A
Other languages
English (en)
Other versions
NO328069B1 (no
Inventor
Moise Azria
Simon David Bateman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20040598L publication Critical patent/NO20040598L/no
Publication of NO328069B1 publication Critical patent/NO328069B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20040598A 2001-08-17 2004-02-10 Farmasoytisk sammensetning for oral avlevering omfattende paratyreoidhormonfragmenter og 5-CNAC, samt anvendelse av sammensetningen for fremstilling av et medikament for behandling av benforstyrrelser. NO328069B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31304801P 2001-08-17 2001-08-17
PCT/EP2002/009181 WO2003015822A1 (en) 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments

Publications (2)

Publication Number Publication Date
NO20040598L true NO20040598L (no) 2004-02-10
NO328069B1 NO328069B1 (no) 2009-11-23

Family

ID=23214149

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040598A NO328069B1 (no) 2001-08-17 2004-02-10 Farmasoytisk sammensetning for oral avlevering omfattende paratyreoidhormonfragmenter og 5-CNAC, samt anvendelse av sammensetningen for fremstilling av et medikament for behandling av benforstyrrelser.

Country Status (26)

Country Link
US (4) US20040242478A1 (no)
EP (1) EP1420827B8 (no)
JP (2) JP4959917B2 (no)
KR (1) KR20040030120A (no)
CN (1) CN1279981C (no)
AT (1) ATE443527T1 (no)
AU (1) AU2002333443C1 (no)
BR (1) BRPI0211932B1 (no)
CA (1) CA2453646C (no)
CO (1) CO5560586A2 (no)
CY (1) CY1109661T1 (no)
DE (1) DE60233803D1 (no)
DK (1) DK1420827T3 (no)
EC (1) ECSP044961A (no)
ES (1) ES2333587T3 (no)
HU (1) HUP0401441A3 (no)
IL (2) IL159714A0 (no)
MX (1) MXPA04001418A (no)
NO (1) NO328069B1 (no)
NZ (1) NZ531018A (no)
PL (1) PL210258B1 (no)
PT (1) PT1420827E (no)
RU (1) RU2322256C2 (no)
SI (1) SI1420827T1 (no)
WO (1) WO2003015822A1 (no)
ZA (1) ZA200400242B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60218842T2 (de) * 2001-06-01 2007-12-20 Novartis Ag Orale verabreichung von parathyroidhormon und calcitonin
US20040242478A1 (en) * 2001-08-17 2004-12-02 Moise Azria 5-cnac as oral delivery agent for parathyroid hormone fragments
US20090170803A1 (en) * 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
ES2436152T3 (es) 2003-07-23 2013-12-27 Novartis Ag Uso de calcitonina en osteoartritis
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
WO2006076692A1 (en) * 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
CA2607901C (en) * 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
SG165397A1 (en) 2005-09-19 2010-10-28 Emisphere Tech Inc Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8- aminocaprylic acid
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
JP2009515535A (ja) * 2005-11-10 2009-04-16 ボード オブ コントロール オブ ミシガン テクノロジカル ユニヴァーシティー クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
WO2008027854A2 (en) * 2006-08-31 2008-03-06 Novartis Ag Pharmaceutical compositions comprising hgh for oral delivery
ES2365648T3 (es) 2007-03-02 2011-10-07 Novartis Ag Administración oral de una calcitonina.
NZ585080A (en) 2007-11-02 2012-05-25 Emisphere Tech Inc Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiency
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
WO2016128972A1 (en) * 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
JPH07502507A (ja) * 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
DE69332105T2 (de) * 1992-09-29 2003-03-06 Inhale Therapeutic Systems, San Carlos Pulmonale abgabe von aktiven fragmenten des parathormons
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ES2297909T3 (es) * 1997-02-07 2008-05-01 Emisphere Technologies, Inc. Compuestos y composiciones para el suministro de agentes activos.
US6537965B1 (en) * 1998-11-25 2003-03-25 The General Hospital Corporation Amino-terminal modified parathyroid hormone (PTH) analogs
DE60017888T2 (de) * 1999-04-05 2006-01-19 Emisphere Technologies, Inc. Dinatrium-salze, monohydrate und ethanol-solvate
US6900344B2 (en) * 2000-03-21 2005-05-31 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
DE60218842T2 (de) 2001-06-01 2007-12-20 Novartis Ag Orale verabreichung von parathyroidhormon und calcitonin
US20040242478A1 (en) * 2001-08-17 2004-12-02 Moise Azria 5-cnac as oral delivery agent for parathyroid hormone fragments
ATE442158T1 (de) * 2003-07-11 2009-09-15 Novartis Pharma Gmbh Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form

Also Published As

Publication number Publication date
WO2003015822A1 (en) 2003-02-27
HUP0401441A2 (hu) 2004-12-28
ATE443527T1 (de) 2009-10-15
US20040242478A1 (en) 2004-12-02
IL159714A (en) 2010-12-30
US20120088725A1 (en) 2012-04-12
CY1109661T1 (el) 2014-08-13
HUP0401441A3 (en) 2012-09-28
CA2453646A1 (en) 2003-02-27
BRPI0211932B1 (pt) 2016-12-06
PL210258B1 (pl) 2011-12-30
RU2004107899A (ru) 2005-05-10
NO328069B1 (no) 2009-11-23
DK1420827T3 (da) 2009-12-21
RU2322256C2 (ru) 2008-04-20
DE60233803D1 (de) 2009-11-05
PL365388A1 (en) 2005-01-10
ECSP044961A (es) 2004-03-23
BR0211932A (pt) 2004-10-26
US20090264367A1 (en) 2009-10-22
JP2009242410A (ja) 2009-10-22
AU2002333443C1 (en) 2009-10-08
CA2453646C (en) 2008-09-30
US20060217313A1 (en) 2006-09-28
ZA200400242B (en) 2004-11-18
JP2005501852A (ja) 2005-01-20
IL159714A0 (en) 2004-06-20
US9272040B2 (en) 2016-03-01
ES2333587T3 (es) 2010-02-24
PT1420827E (pt) 2009-12-15
JP4959917B2 (ja) 2012-06-27
CN1543357A (zh) 2004-11-03
EP1420827B8 (en) 2009-12-23
NZ531018A (en) 2006-03-31
EP1420827B1 (en) 2009-09-23
CO5560586A2 (es) 2005-09-30
MXPA04001418A (es) 2004-05-27
CN1279981C (zh) 2006-10-18
AU2002333443B2 (en) 2006-06-29
EP1420827A1 (en) 2004-05-26
SI1420827T1 (sl) 2010-01-29
KR20040030120A (ko) 2004-04-08

Similar Documents

Publication Publication Date Title
NO20040598L (no) 5-CNAC som oralt avleveringsmiddel for paratyreoidhormonfragmenter.
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
MXPA06012980A (es) Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
CL2012000348A1 (es) Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica.
ATE500218T1 (de) Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
IL220043A0 (en) Methods for producing ??-galactosidase a compositions
GT199700009AA (es) Terapia combinada para la osteoporosis
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
ATE356631T1 (de) Orale verabreichung von parathyroidhormon und calcitonin
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
CY1108413T1 (el) Ενεσιμη φαρμακευτικη συνθεση που περιλαμβανει αιθανολη για την αγωγη των δισκοπαθειων
PL370361A1 (en) Alkyl urea retinoid agonists i
HK1068606A1 (en) Novel aminobenzoephenones
PL370459A1 (en) Substituted urea retinoid agonists ii
AU2003286617A8 (en) Calcitonin drug-oligomer conjugates, and uses thereof
MXPA03006157A (es) Metodo de terapia de reemplazo de hormona y su forma de administracion.
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
HUP0203741A2 (hu) Eljárás oszteoporózis kezelésére
IL125983A0 (en) Pharmaceutical composition comprising factor xiiia
TW200509960A (en) Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
ITMI20031303A1 (it) Composizioni per impianti sottocutanei contenenti almeno un ormone steroideo per la terapia ormonale sostitutiva e per la contraccezione.
UY26651A1 (es) Terapia combinada para la osteoporosis

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees